Shandong Boan Biotechnology Co Ltd
HKEX:6955
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8.08
18.28
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Shandong Boan Biotechnology Co Ltd stock under the Base Case scenario is 12.92 HKD. Compared to the current market price of 8.08 HKD, Shandong Boan Biotechnology Co Ltd is Undervalued by 37%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Shandong Boan Biotechnology Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Shandong Boan Biotechnology Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Shandong Boan Biotechnology Co Ltd
Balance Sheet Decomposition
Shandong Boan Biotechnology Co Ltd
Current Assets | 749m |
Cash & Short-Term Investments | 172.1m |
Receivables | 346.4m |
Other Current Assets | 230.5m |
Non-Current Assets | 1.8B |
PP&E | 659.9m |
Intangibles | 1.1B |
Current Liabilities | 555.6m |
Accounts Payable | 237.2m |
Other Current Liabilities | 318.4m |
Non-Current Liabilities | 601m |
Long-Term Debt | 482.4m |
Other Non-Current Liabilities | 118.6m |
Earnings Waterfall
Shandong Boan Biotechnology Co Ltd
Revenue
|
719.8m
CNY
|
Cost of Revenue
|
-186.5m
CNY
|
Gross Profit
|
533.4m
CNY
|
Operating Expenses
|
-451.4m
CNY
|
Operating Income
|
82m
CNY
|
Other Expenses
|
-20.2m
CNY
|
Net Income
|
61.8m
CNY
|
Free Cash Flow Analysis
Shandong Boan Biotechnology Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Shandong Boan Biotechnology Co Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Shandong Boan Biotechnology Co Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shandong Boan Biotechnology Co Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Shandong Boan Biotechnology Co Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shandong Boan Biotechnology Co Ltd
According to Wall Street analysts, the average 1-year price target for Shandong Boan Biotechnology Co Ltd is 11.53 HKD with a low forecast of 11.41 HKD and a high forecast of 11.87 HKD.
Dividends
Current shareholder yield for Shandong Boan Biotechnology Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Shandong Boan Biotechnology Co Ltd stock under the Base Case scenario is 12.92 HKD.
Compared to the current market price of 8.08 HKD, Shandong Boan Biotechnology Co Ltd is Undervalued by 37%.